Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2020-02-04 AGM Information
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Intron Biotechnology, detailing the date, location, agenda items (financial statement approval, director/auditor appointments, and remuneration limits), and the adoption of electronic voting. This document serves as the official solicitation and notification for shareholders regarding the meeting, which falls under the category of Proxy Solicitation & Information Statement.
2020-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) where company insiders report their shareholdings and changes therein. This falls under the category of Director's Dealing (DIRS), as it details personal share transactions and ownership status by a company executive (Kim Soo Jin).
2020-01-06 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory notice of a corporate action. Given it is a specific regulatory announcement that does not fit into the other categories like dividend or share issuance, it is classified as a general regulatory filing.
2019-12-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by a major shareholder (Yoon Seong-jun) and their special relations, including stock purchase and collateral agreements. This falls under the category of 'Major Shareholding Notification' (MRQ).
2019-12-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details share acquisitions by a director (Yoon Seong Jun) of Intron Biotechnology. This type of filing is a standard regulatory disclosure for insider trading/director dealings.
2019-12-12 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '인트론바이오테크놀로지' (iNtRON Biotechnology, Inc.) covering the period from 2019-01-01 to 2019-09-30. It contains detailed financial information, business descriptions, capital changes, and management disclosures, which are characteristic of a formal quarterly financial report. It is not an announcement of a report, but the report itself. 9M 2019
2019-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.